SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Lpath, Inc. (LPTN)

LPTN RSS Feed
Add LPTN Price Alert      Hide Sticky   Hide Intro
Moderator: Value_Investor, tob999
Search This Board:
Last Post: 7/22/2016 3:24:00 PM - Followers: 46 - Board type: Free - Posts Today: 0

Lpath Inc.






Lpath Incorporated
4025 Sorrento Valley Blvd.
San Diego, CA 92121
Tel: 858-678-0800
FAX: 858-678-0900
 

Lpath, Inc. is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines.
 

Lpath's ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders.



 

Lpath, Inc. focuses on the discovery and development of monoclonal antibodies that target bioactive lipids. Numerous lipids that contribute to disease have now been identified through the various efforts of academics and industry. However, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2™ platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.

Lpath has leveraged ImmuneY2 and generated monoclonal antibody drug candidates against several bioactive lipids, including sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), leukotrienes (LTs) and others.
 

Lpath is currently advancing LpathomabTM, a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized to be involved in disorders of the central nervous system (including pain, traumatic brain injury, neurodegeneration), fibrosis, ocular disease and cancer. Lpathomab has demonstrated strong preclinical activity in several animal models of these diseases, including neuropathic pain, diabetic neuropathy, traumatic brain injury and spinal cord injury. Lpathomab is currently in a phase 1 clinical trial.

The company is applying ImmuneY2 to other bioactive lipid targets, many of which are involved in important disease processes (e.g. inflammation, cancer, pain, asthma, and others) thereby adding to our pipeline of novel antibody-based drug candidates.

Lpath has a broad and deep intellectual property position in the bioactive lipid area, with over 50 issued or pending patents in the U.S., with corresponding international applications. Most of these patents were developed in-house using our proprietary technologies and expertise.


Executive Team
 

Gary Atkinson - Chief Executive Officer, Chief Financial Officer

Background: Mr. Atkinson has more than 20 years of financial management experience. Prior to joining Lpath, he served as the Chief Financial Officer for three private life science companies. In addition, Mr. Atkinson was the Vice President of Finance at Isis Pharmaceuticals, a publicly held pharmaceutical research and development company. He began his career with Ernst & Young, where he earned his CPA designation. Mr. Atkinson is a graduate of Brigham Young University.

Dario A. Paggiarino, M.D. - Sr. Vice President & Chief Development Officer

Background: Dr. Paggiarino brings to Lpath more than 25 years of experience in the pharmaceutical industry, having directed global development programs in a number of therapeutic areas including ophthalmology, pain, inflammatory conditions, and oncology. Most recently, Dr. Paggiarino served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis. He also served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen(R). Earlier in his career, he held R&D positions of increasing responsibility at Angelini Pharmaceuticals, a privately owned company, ultimately serving as president. Later he joined Pharmacia Global R&D where he was clinical program director of ophthalmology with responsibilities for Xalatan(R), the leading glaucoma therapy in the world, and ocular devices such as viscoelastics (Healon(R)) and intraocular lenses (CeeOn(R), Tecnis(R)). Dr. Paggiarino earned his degree in Medicine and General Surgery at the University of Rome La Sapienza and has authored numerous scientific articles.

Gary Woodnutt, Ph.D. - Sr. Vice President & Chief Scientific Officer

Background: Dr. Woodnutt brings to Lpath extensive experience in drug discovery and pharmaceutical research. Prior to joining Lpath, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years and rose to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.

Roger Sabbadini, Ph.D. - Vice President, Scientific Founder

Background: Dr. Sabbadini was a Professor of Biology for 32 years at San Diego State University and is currently a Professor Emeritus of Biology. He founded three biotechnology companies, including Lpath, that were incubated out of SDSU. Dr. Sabbadini has been interested in the role of bioactive lipids in  various diseases, including cancer, ocular disorders, neurotrauma, neuropathic pain, inflammation and heart disease. Dr. Sabbadini’s research focused on developing novel antibody-based therapeutics against bioactive lipids such as S1P  and LPA and these antibodies have been advanced into human clinical trials. Dr. Sabbadini earned his Ph.D. at the University of California, Davis.

Leigh Hsu, Ph.D., M.B.A. - Vice President, Corporate Development & Strategy

Background: Dr. Hsu has more than 15 years of business experience in the biotech industry. Prior to Lpath, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics (which became a subsidiary of Schering AG, now Bayer). Dr. Hsu played a key role in Lpath's $517 million licensing deal with Pfizer for iSONEP™, and has extensive deal experience with organizations like Wyeth and GE Healthcare, as well as with several academic and research organizations, including the University of California, the University of Texas, Southwestern Medical Center and the Veterans Medical Research Foundation. He has published numerous scientific papers, primarily in the area of the molecular basis of neurodegenerative diseases. Dr. Hsu received his Ph.D. in Molecular Pathology from the University of California, San Diego, and his M.B.A. from the University of California, Irvine.


Good read:  http://seekingalpha.com/article/412101-why-morgan-joseph-expects-triple-digit-gains-for-this-pfizer-partner

ASONEP
http://www.clinicaltrials.gov/ct2/show/NCT00661414
Share Structure
 

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
LPTN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#672  Sticky Note LPTN has Zero Debt which is a Sought-After Value_Investor 07/21/16 07:14:00 PM
#682   LOL, the sick MM manipulated the price down Value_Investor 07/22/16 03:24:00 PM
#681   LPTN Warning Shorting Low Float Bio Tech Stocks Stockexpertpro 07/22/16 01:09:17 PM
#680   LPTN should close above $2.3 today since the Value_Investor 07/22/16 12:04:13 PM
#679   Wow, LPTN exploded to $2.65 today! It will Value_Investor 07/22/16 11:54:07 AM
#678   Crazy low $5.1M market cap!! Insane! tob999 07/22/16 11:13:57 AM
#677   A close above 2.20 will be nice. Bullish Shaka_Zulu 07/22/16 11:04:21 AM
#676   +21% on substantially increased volume! News comin? tob999 07/22/16 10:23:51 AM
#675   Ibox updated and redesigned. tob999 07/22/16 10:23:10 AM
#674   I can smarten up the Ibox if there tob999 07/22/16 09:17:55 AM
#673   Float 2.O3 million !!!!! zino 07/21/16 11:28:10 PM
#672   LPTN has Zero Debt which is a Sought-After Value_Investor 07/21/16 07:14:00 PM
#671   Good timing agreed! Bring on the boom..with this tob999 07/21/16 05:48:36 PM
#670   Nice entry at good timing! The Book Value Value_Investor 07/21/16 12:51:38 PM
#669   Yes. LPTN is Hyper Undervalued now --- $3.71 Value_Investor 07/21/16 12:47:06 PM
#668   bought in this morning...glta zino 07/21/16 12:42:40 PM
#667   can fly here O/S 2,OOO,OOO zino 07/21/16 12:42:24 PM
#666   We all saw that kinds of manipulation efforts Value_Investor 07/20/16 12:39:46 PM
#665   Undervalued indeed. tob999 07/20/16 12:34:00 PM
#664   LPTN hit the New high $2.04 so far! Value_Investor 07/20/16 12:31:41 PM
#663   Being held down on low volume. Every time tob999 07/20/16 12:31:09 PM
#662   LOL, LPTN has $3.71 Per Share Huge Book Value_Investor 07/19/16 02:53:51 PM
#661   LPTN is up 11.48% in the AH session Value_Investor 07/18/16 07:12:11 PM
#660   Who have kept manipulating LPTN down while it Value_Investor 07/18/16 01:57:57 PM
#659   LPTN has measly 2.36M shares Hyper Tiny OS Value_Investor 07/17/16 01:05:31 PM
#658   Nice bounce yesterday! LPTN hit $1.96 again! We Value_Investor 07/16/16 03:06:59 PM
#657   Grabbed a few more here today/yesterday. Waiting for tob999 07/15/16 03:19:45 PM
#656   LOL, those very sick MMs manipulated LPTN down Value_Investor 07/15/16 11:30:02 AM
#655   Yes. LPTN has already bottomed out at $1.71 Value_Investor 07/14/16 01:27:04 PM
#654   Tic toc till monster move here in LPTN. tob999 07/14/16 01:17:21 PM
#653   LPTN is up 2.21% so far! $3.71 per Value_Investor 07/14/16 01:00:47 PM
#652   Huge Discount price levels now comparing to that Value_Investor 07/13/16 12:12:04 PM
#651   Agreed. Wall Street is the biggest Cesspool in Value_Investor 07/12/16 01:12:44 PM
#650   Crime is alive and well and unchallenged in tob999 07/11/16 06:53:22 PM
#649   LOL, the sick MM just manipulated the price Value_Investor 07/11/16 04:02:44 PM
#648   GL bro! I averaged down to under $2 tob999 07/11/16 02:41:45 PM
#647   I see. I still have a lots of Value_Investor 07/11/16 02:24:37 PM
#646   Lucky if you have powder bro! I'm tapped tob999 07/11/16 02:20:10 PM
#645   No worry, my friend! I actually hope LPTN Value_Investor 07/11/16 02:18:05 PM
#644   With this pathetic low volume substantive news is tob999 07/11/16 02:14:53 PM
#643   IMO, News is not that important for any Value_Investor 07/11/16 11:23:32 AM
#642   Miniscule float for sure! Let's have some substantive tob999 07/11/16 09:09:55 AM
#641   Yes. LPTN has measly 1.9M shares Hyper Tiny Value_Investor 07/08/16 05:01:12 PM
#640   I actually hope the price of LPTN to Value_Investor 07/08/16 03:13:01 PM
#639   Yep me too. No worries averaging down here. tob999 07/08/16 03:03:08 PM
#638   Today is an huge loading opportunity to steal Value_Investor 07/08/16 02:31:49 PM
#637   Yep! I've been quietly loading the last week tob999 07/08/16 02:28:10 PM
#636   LPTN has bottomed out at $1.82 and ready Value_Investor 07/08/16 12:33:51 PM
#635   106M at .00 on the bid? WTF? tob999 07/07/16 03:55:42 PM
#634   Interest has died on this low floater. Bring tob999 07/05/16 01:38:10 PM
#633   Bring your swingers back and run it up tob999 07/03/16 03:56:21 PM
PostSubject